# Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

> **NCT03083210** · PHASE4 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 28 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Lanreotide

## Key facts

- **NCT ID:** NCT03083210
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-05
- **Primary completion:** 2020-02
- **Final completion:** 2020-02
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2019-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03083210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03083210, "Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03083210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*